Abstract
Pharmacoeconomics is a relatively new discipline, which is becoming increasingly useful in the current climate of medical advances that continue despite limited access to healthcare resources. Pharmacoeconomics may be used as a tool, assisting healthcare decision-makers to select clinically beneficial therapies and weigh clinical gain against expenditure. Cefotaxime has been shown in many studies to be a cost-effective antibiotic agent; its monetary value being augmented by its use in low dose, low frequency regimens. This cost-effectiveness, combined with a maintained broad spectrum of antibiotic activity, low propensity for selecting resistant bacterial strains and high therapeutic index, make cefotaxime an ideal antibiotic agent in many indications involving mild-to-moderate infection by susceptible organisms.
| Original language | English |
|---|---|
| Pages (from-to) | 23-33 |
| Number of pages | 10 |
| Journal | Research and Clinical Forums |
| Volume | 19 |
| Issue number | 4 |
| Publication status | Published - 1997 |